替换
查找内容:
替换为:
全部替换
插入链接
链接网址:
链接显示标题:
请选择网址类型
点我插入链接
插入文件
文件名称:
文件显示标题:
请选择文件类型
点我插入文件
发现错误 发表观点

原文内容

反馈意见

提交 正在提交..... 反馈历史

复制下面的地址分享给好友

确定 正在提交.....
train

你好,

关闭
提交 重做 重新开始 关闭
跳转
  • 新建同级
  • 新建子级
  • 删除
  • 重命名
选择收藏夹
新建收藏夹
公开

取消 确定

1. 基本信息
姓名:
企业:
职位:
联系方式:
邮箱:
2. 请在此填写您的问题,我们将优先安排答疑
提交

报名成功!
课程观看链接如下:
请添加课程助理微信,获得更多信息:
确认
确定
取消 确认

识林

  • 知识
  • 视频
  • 社区
  • 政策法规
    • 国内药监
    • FDA
    • EU
    • PIC/S
    • WHO
    • ICH
    • MHRA
    • PMDA
    • TGA
  • 研发注册
    • 概览
    • 监管动态
    • 研究专题
  • 生产质量
    • 概览
    • 监管动态
    • 各国GMP
    • 中国GMP
    • 中国GMP指南
    • GMP对比
    • 检查缺陷
    • 研究专题
  • 主题词库
  • 帮助中心
  • 关于识林
    • 识林介绍
    • 识林FAQs
    • 功能介绍
    • 团队诊断
    • 联系我们
  • 30天免登录

    忘记密码?

FDA通过举办数据策略现代化公开会议来提高机构的科学和技术能力

首页 > 资讯 > FDA通过举办数据策略现代化公开会议来提高机构的科学和技术能力

页面比对

出自识林

FDA通过举办数据策略现代化公开会议来提高机构的科学和技术能力
TMAP
页面比对
笔记

2020-01-07 FDA

跳转到: 导航, 搜索

FDA continues to advance agency-wide scientific and technical capabilities by holding public meeting on modernization of data strategy

The following quote is attributed to FDA Commissioner Stephen M. Hahn, M.D.:

“Data are the foundation of our most important work as a science-based regulatory agency—from reviewing medical products to identifying the source of a food-borne illness outbreak.”

“Because data are so essential to what we do, we are committed to ensuring that our mechanisms for collecting, reviewing and analyzing data are equally as sophisticated as the scientific advances that we are reviewing.”

The following quote is attributed to FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D.:

“Critical steps in transforming our computing and technology infrastructure are reflected in the FDA’s Technology Modernization Action Plan. This plan is an important step in closing the gap between scientific advances and the computing solutions needed to translate those advances into new therapies for patients.”

“The next step is to combine our computing capability with state-of-the-art approaches in data management, analysis and decision-making. We will work with internal and external experts on how to best approach important topics like data stewardship, strategy, standards and more. Our March 27 public meeting we’re announcing today provides a critical opportunity for public input and engagement on this important topic. Data strategy relates directly to the products we regulate, the efficiency of our agency and our public health mission.”

  • Today, the U.S. Food and Drug Administration announced it is holding a public meeting on March 27, 2020 at the FDA’s White Oak campus on “Modernizing FDA’s Data Strategy.”
  • The purpose of the public meeting and the request for comments is to discuss possible agency-level approaches to modernizing the FDA’s data strategy, including approaches to data quality, data stewardship, data exchange and data analytics.
  • This meeting is part of the FDA’s efforts to modernize technology used at the agency, as detailed in the

Technology Modernization Action Plan (TMAP), released in September 2019. The TMAP describes steps the FDA is taking to modernize the use of technology, including computer hardware, software, cloud-based solutions and data exchange. The FDA’s data strategy meeting announced today is the next step in these efforts.

  • The FDA will continue to provide updates on the TMAP, including opportunities for future engagement with the agency, such as innovation challenges designed to encourage collaboration with the FDA.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

【来源】
FDA continues to advance agency-wide scientific and technical capabilities by holding public meeting on modernization of data strategy

取自“https://login.shilinx.com/wiki/index.php?title=FDA%E9%80%9A%E8%BF%87%E4%B8%BE%E5%8A%9E%E6%95%B0%E6%8D%AE%E7%AD%96%E7%95%A5%E7%8E%B0%E4%BB%A3%E5%8C%96%E5%85%AC%E5%BC%80%E4%BC%9A%E8%AE%AE%E6%9D%A5%E6%8F%90%E9%AB%98%E6%9C%BA%E6%9E%84%E7%9A%84%E7%A7%91%E5%AD%A6%E5%92%8C%E6%8A%80%E6%9C%AF%E8%83%BD%E5%8A%9B”
上一页: 欧盟延长安全信号检测试点至_2021_年底
下一页: 零483代表什么_–_透过数据看合规
相关内容
相关新闻
  • FDA 推出技术现代化行动计划...
  • FDA 宣布数据现代化行动计划
热点新闻
  • ICH 发布新 Q1 稳定性指南...
  • 【直播】25年4月全球法规月报...
  • 【识林新文章】中国无菌附录对...
  • 【识林新工具】AI知识助手,AI...
  • VHP(过氧化氢蒸汽)的“脆弱...

 反馈意见

Copyright ©2011-2025 shilinx.com All Rights Reserved.
识林网站版权所有 京ICP备12018650号-2 (京)网药械信息备字(2022)第00078号
请登录APP查看
打开APP